Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)
Cell Communication and Signaling · 12.03.2024 · 22 (1)
DOI: 10.1186/s12964-024-01544-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Communication and Signaling, online erschienen am 12.03.2024. Verfasst von Jun Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Heterocyclic Compounds. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Shenkang Hospital Development Center.
Abstract (Originalsprache)
Background
The incidence of multiple myeloma (MM), a type of blood cancer affecting monoclonal plasma cells, is rising. Although new drugs and therapies have improved patient outcomes, MM remains incurable. Recent studies have highlighted the crucial role of the chemokine network in MM’s pathological mechanism. Gaining a better understanding of this network and creating an overview of chemokines in MM could aid in identifying potential biomarkers and developing new therapeutic strategies and targets.
Purpose
To summarize the complicated role of chemokines in MM, discuss their potential as biomarkers, and introduce several treatments based on chemokines.
Methods
Pubmed, Web of Science, ICTRP, and Clinical Trials were searched for articles and research related to chemokines. Publications published within the last 5 years are selected.
Results
Malignant cells can utilize chemokines, including CCL2, CCL3, CCL5, CXCL7, CXCL8, CXCL12, and CXCL13 to evade apoptosis triggered by immune cells or medication, escape from bone marrow and escalate bone lesions. Other chemokines, including CXCL4, CCL19, and CXCL10, may aid in recruiting immune cells, increasing their cytotoxicity against cancer cells, and inducing apoptosis of malignant cells.
Conclusion
Utilizing anti-tumor chemokines or blocking pro-tumor chemokines may provide new therapeutic strategies for managing MM. Inspired by developed CXCR4 antagonists, including plerixafor, ulocuplumab, and motixafortide, more small molecular antagonists or antibodies for pro-tumor chemokine ligands and their receptors can be developed and used in clinical practice. Along with inhibiting pro-tumor chemokines, studies suggest combining chemokines with chimeric antigen receptor (CAR)-T therapy is promising and efficient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
- Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
- Department of Hematology, Shengli Oilfield Central Hospital, Dongying, 257099, China. luguangshandong@163.com.
- Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. houjian@medmail.com.cn.
Förderung
- Shanghai Shenkang Hospital Development Center
Zitieren
APA
Du, J., Lin, Z., Fu, X. H., Gu, X. R., Lu, G., & Hou, J. (2024). Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM). Cell Communication and Signaling, 22(1). https://doi.org/10.1186/s12964-024-01544-7
Vancouver
Du J, Lin Z, Fu XH, Gu XR, Lu G, Hou J. Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM). Cell Communication and Signaling. 2024;22(1). doi:10.1186/s12964-024-01544-7
BibTeX
@article{Du2024,
author = {Du, Jun and Lin, Zheng and Fu, Xue-Hang and Gu, Xiao-Ran and Lu, Guang and Hou, Jian},
title = {Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)},
journal = {Cell Communication and Signaling},
year = {2024},
volume = {22},
number = {1},
doi = {10.1186/s12964-024-01544-7}
}
EUVIMED